title: Schedules of Controlled Substances: Placement of Brivaracetam   Into Schedule V. Interim final rule, with request for comments.
abstract: The Drug Enforcement Administration is placing the substance brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also referred to as BRV; UCB-34714; Briviact) (including its salts) into schedule V of the Controlled Substances Act. This scheduling action is pursuant to the Controlled Substances Act, as revised by the Improving Regulatory Transparency for New Medical Therapies Act which was signed into law on November 25, 2015.
mesh_terms: D002492:Central Nervous System Depressants / Q000145:classification; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D006801:Humans; D011760:Pyrrolidinones / Q000145:classification*; D014481:United States
chemical_list: D002492:Central Nervous System Depressants; D011760:Pyrrolidinones